How many insider trades does FilingIQ track for ATAI?

FilingIQ tracks 93 Form 4 insider transactions for ATAI (AtaiBeckley Inc.), covering filings from Jun 22, 2021 onwards. 18 of those were filed in the last 90 days.

Are ATAI insiders net buyers or net sellers?

Across the full Form 4 history for ATAI, 30 transactions (32%) were open-market purchases and 12 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ATAI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ATAI in?

AtaiBeckley Inc. (ATAI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.29B.

ATAI insider trading

NasdaqGM Healthcare

AtaiBeckley Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

32% / 13%

Market cap

$1.29B

About AtaiBeckley Inc.

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Company website: www.ataibeckley.com

ATAI insider activity at a glance

FilingIQ has scored 93 insider transactions for ATAI since Jun 22, 2021. The most recent filing in our index is dated Apr 20, 2026.

Across the full history, 30 open-market purchases and 12 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ATAI insider trades is 50.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ATAI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ATAI?: FilingIQ tracks 93 Form 4 insider transactions for ATAI (AtaiBeckley Inc.), covering filings from Jun 22, 2021 onwards. 18 of those were filed in the last 90 days.
Are ATAI insiders net buyers or net sellers?: Across the full Form 4 history for ATAI, 30 transactions (32%) were open-market purchases and 12 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ATAI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ATAI in?: AtaiBeckley Inc. (ATAI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.29B.

Methodology & sources

Every ATAI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.